Status:
COMPLETED
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix
Lead Sponsor:
University of Toronto
Conditions:
Herpes Simplex Type Two Infection
HIV Infections
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Herpes simplex virus type 2 (HSV2), the most common cause of genital herpes, increases a woman's risk of HIV acquisition from 3-6 fold, perhaps because HSV2-infected women have increased numbers of HI...
Eligibility Criteria
Inclusion
- Female
- HSV2 infected
Exclusion
- HIV infected
- Pregnant
- Taking HSV2 therapy
- Current/recent (past 3 months) genital infection
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00946556
Start Date
April 1 2010
End Date
May 1 2011
Last Update
March 22 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Women's Health In Women's Hands
Toronto, Ontario, Canada